Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.2% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific Inc (TMO) is a leading company in the field of scientific research and laboratory equipment. Today, the stock showed a strong bullish movement, rising by 4.9%.

Why is Thermo Fisher Scientific Inc going up?

TMO stock is up 5.2% on Jun 25, 2026 14:06

• The partnership with Eli Lilly's TuneLab in the AI-driven drug discovery platform could have boosted investor confidence in TMO's future growth prospects.
• Despite facing challenges such as funding cuts and China softness, TMO's ability to beat Q1 2026 estimates for revenue and EPS might have reassured investors about the company's resilience.
• TMO's undervaluation according to GuruFocus' GF Value™ could have attracted value investors, contributing to the stock's upward momentum.
• Outperforming the broader market on consecutive days showcases TMO's relative strength and stability in uncertain market conditions, further bolstering investor sentiment.

TMO Price Chart

TMO Technical Analysis

TMO News

Charles River (CRL) Deepens Lilly AI Partnership: What Does TuneLab Access Mean for Its Moat?

Charles River Laboratories (CRL) recently announced a collaboration with Eli Lilly's TuneLab, an AI/ML-driven drug discovery platform, to provide nonclinical testing services. This partnership integrates Charles River into an AI-enabled ecosystem, potentially enhancing its role in preclinical research, especially in data-rich areas like cell and gene therapies. The move aims to offset slower revenue growth and address the emerging risk posed by the accelerated adoption of non-animal testing methods.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-crl/charles-river-laboratories-international/news/charles-river-crl-deepens-lilly-ai-partnership-what-does-tun

Price to sales forward of Baytex Energy Corp. – GETTEX:B5X

This page from TradingView displays financial information, specifically the "Price to sales forward" for Baytex Energy Corp. (B5X) on the Gettex exchange. It appears to be a stub or an incomplete data visual, as no specific values are presented, only placeholders for "Period," "Value," "Change," and "Change %." The page also includes extensive navigation and legal information related to TradingView.

https://www.tradingview.com/symbols/GETTEX-B5X/financials-statistics-and-ratios/price-sales-fwd/

Thermo Fisher Scientific Inc (TMO) Stock Up 4.9% and Still Undervalued

Thermo Fisher Scientific Inc (TMO) saw its stock rise by 4.9% on June 24, 2026, reaching $492.20, although it remains undervalued according to GuruFocus' GF Value™. The stock's GF Score™ of 82/100 indicates strong overall performance, particularly in profitability and valuation, despite recent insider selling and average financial strength and momentum scores. TMO is considered "Modestly Undervalued," presenting a potential opportunity for investors.

https://www.gurufocus.com/news/8930595/thermo-fisher-scientific-inc-tmo-stock-up-49-and-still-undervalued-gf-score-82100

Thermo Fisher Is Down 27% From Its Highs. The EPS Trough Looks Like It Is Already Behind the Company

Thermo Fisher Scientific (TMO) is down 27% from its highs, facing headwinds from funding cuts, China softness, and tariffs, yet it still beat Q1 2026 estimates for revenue and EPS. The company's EPS has essentially flatlined for the past three years but is forecasted to grow significantly from 2026 onward, with analysts projecting a cyclical recovery. TIKR's valuation model suggests a ~$722 target by 2030, indicating a potential buying opportunity given the stock's current discount to historical levels.

https://www.tikr.com/blog/thermo-fisher-is-down-27-from-its-highs-the-eps-trough-looks-like-it-is-already-behind-the-company?

Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market

Shares of Thermo Fisher Scientific Inc. (TMO) rose 4.87% on Wednesday, closing at $492.20. The stock outperformed the broader market, as the Dow Jones Industrial Average gained 0.35% while the S&P 500 Index fell 0.10%. This marks the second consecutive day of gains for Thermo Fisher Scientific.

https://www.marketwatch.com/data-news/thermo-fisher-scientific-inc-stock-rises-wednesday-outperforms-market-3771052d-16baeb1196f2?mod=goog_fin_scmw

Trending Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Up 5.4% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Up 5.3% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.2% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.5% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.5% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 10.0% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 7.3% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.6% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 6.7% Today

Thermo Fisher Scientific Inc Price History

23.03.2026 - TMO Stock was down 10.0%

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

23.03.2026 - TMO Stock was down 11.0%

• Thermo Fisher Scientific reported strong first-quarter results with revenue and earnings growth, driven by acquisitions and new product launches.
• Despite beating earnings estimates, the stock experienced a bearish movement due to concerns over modest organic growth and a cautious full-year revenue outlook.
• Investors focused on the company's reliance on acquisitions for revenue increase and the slightly below-consensus full-year revenue guidance, leading to the stock decline.
• The market reaction suggests that while the company's financials are solid, concerns about future organic growth and demand are weighing on investor sentiment, resulting in the bearish movement of the stock.

23.03.2026 - TMO Stock was down 10.5%

• Thermo Fisher Scientific's stock saw a bearish trend due to weaker-than-expected organic growth, which raised concerns about demand despite exceeding revenue and EPS expectations.
• The market reacted negatively to the company's reliance on acquisitions for growth, with organic revenue growth at only 1%, indicating a preference for sustainable core business performance.
• Despite successful capital deployment, new product launches, and strategic partnerships, investors prioritized the quality of underlying business growth over the earnings beat, leading to the stock decline.
• The bearish movement highlights the market's emphasis on sustainable growth and operational excellence rather than short-term financial metrics, impacting Thermo Fisher's stock performance negatively.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

24.05.2026 - TMO Stock was up 5.1%

• Thermo Fisher Scientific Inc (TMO) saw a significant 3.84% increase in its stock price, driven by factors such as product innovation, attractive valuation, and increased institutional buying.
• The integration of AI into its research tools and expanded services has positioned TMO as a tech-driven healthcare leader, contributing to investor optimism and institutional confidence in its long-term potential.
• Despite facing macroeconomic uncertainties and company-specific risks, resilient first-quarter earnings and an upward revision of full-year guidance have further fueled the positive sentiment surrounding TMO's stock.
• TMO's outperformance compared to the broader market indices like the S&P 500 and Dow Jones Industrial Average showcases investor confidence in the company's growth prospects, despite trading below its 52-week high.

24.05.2026 - TMO Stock was up 5.0%

• The positive reception of TMO's AI tools at the BIO International convention is a key factor in the company's recent bullish movement, emphasizing its dedication to innovation and expansion.
• TMO's undervaluation, supported by consistent revenue growth and expanding profit margins, has attracted investors and contributed to the stock's upward trajectory.
• Despite facing challenges from academic and government sectors and external pressures, TMO's concentrated efforts on AI-driven solutions and drug development have resonated positively with investors.
• TMO's stock has demonstrated resilience by outperforming broader market declines, reflecting investor confidence in the company's future prospects and its ability to navigate industry obstacles successfully.

09.05.2026 - TMO Stock was up 5.1%

• Despite a positive market trend, an adjustment in rating to Hold from Buy by a financial institution and uncertainties regarding future growth targets post-2027 may have impacted investor confidence.
• On the other hand, another financial firm's endorsement of TMO's performance emphasized its strong market presence and successful growth strategies through acquisitions, contrasting with the more cautious view of the first institution.
• The recent unveiling of new mass spectrometry platforms and AI software at a notable event by Thermo Fisher Scientific likely boosted market optimism and drove an upward movement in its stock.
• Evaluating TMO alongside other AI companies in the market indicates that investors are comparing potential returns and risks within the sector, which could influence the stock's performance.

25.05.2026 - TMO Stock was up 5.2%

• The partnership with Eli Lilly's TuneLab in the AI-driven drug discovery platform could have boosted investor confidence in TMO's future growth prospects.
• Despite facing challenges such as funding cuts and China softness, TMO's ability to beat Q1 2026 estimates for revenue and EPS might have reassured investors about the company's resilience.
• TMO's undervaluation according to GuruFocus' GF Value™ could have attracted value investors, contributing to the stock's upward momentum.
• Outperforming the broader market on consecutive days showcases TMO's relative strength and stability in uncertain market conditions, further bolstering investor sentiment.

28.04.2026 - TMO Stock was up 8.0%

• Thermo Fisher's stock saw a significant increase of 5.14%, propelled by the company's strong Q1 2026 results that surpassed expectations, leading to a positive revision of their full-year EPS guidance.
• Investor confidence in Thermo Fisher's technological advancements was further reinforced with the introduction of new advanced mass spectrometers at a major conference.
• Despite the optimistic market movement, concerns arise regarding the potential impact on adjusted EPS from the sale of its microbiology business and the overall macroeconomic challenges facing the company. Monitoring Thermo Fisher's strategies to address these obstacles will be crucial for investors.

28.04.2026 - TMO Stock was up 5.5%

• The recent bullish movement in TMO's stock can be linked to its target of achieving a 7% organic revenue compound annual growth rate (CAGR) as disclosed at its recent Investor Day, indicating strong growth potential and investor support.
• While there are concerns about the sustainability of long-term growth, TMO's strategic actions, including the launch of a new bioanalytical and biomarker laboratory in Sweden, underscore its dedication to meeting market needs and strengthening its industry position.
• The announcement of a quarterly cash dividend of $0.47 per common share showcases TMO's financial stability and commitment to shareholders, fostering positive investor sentiment.
• Despite the allure of alternative opportunities in AI stocks for potentially higher short-term returns, TMO's focus on long-term growth and strategic investments positions it well for continued success in the life sciences sector.

28.04.2026 - TMO Stock was up 7.3%

• Thermo Fisher (TMO) showcased its cutting-edge mass spectrometers at a major conference, highlighting its commitment to advancing scientific research and decision-making processes.
• Despite insider selling activity, the company's solid profitability and ambitious 7% annual growth target signal confidence in its future prospects.
• RBC Capital's Sector Perform rating and price objective suggest a balanced view on TMO's performance, acknowledging market improvements while cautioning about long-term growth sustainability.
• The emphasis on meeting increased demand for advanced drug development solutions and strengthening global networks reflects TMO's strategic positioning for growth, despite suggestions of potentially higher returns in certain AI stocks.